Sort   by:  
 Page size 
MetabolomicsMolecular networking coupled to high-resolution mass spectrometry fragmentation reveals a multitude of urinary antihypertensive drug metabolites
Mass spectrometry is the current technique of choice in studying drug metabolism. High-resolution mass spectrometry (HR-MS) in combination with fragment analysis (MS/MS) has the potential to contribute to rapid advances in this field. However, the data emerging from such fragmentation spectra pose c...
2016-05-23 | MTBLS307 | MetaboLights
MetabolomicsMetabolic Drug Response Phenotyping in Colorectal Cancer Organoids by LC-QTOF-MS
As metabolic rewiring is crucial for cancer cell proliferation, metabolic phenotyping of patient-derived organoids is desirable to identify drug-induced changes and trace metabolic vulnerabilities of tumor subtypes. We established a novel protocol for metabolomic and lipidomic profiling of colorecta...
2021-10-12 | MTBLS2130 | MetaboLights
ProteomicsDesign of combination therapeutics from protein response to drugs in ovarian cancer cells
High-grade serous ovarian cancer (HGSOC) remains the most lethal gynecologic malignancy and novel treatment approaches are needed. Here, we used unbiased quantitative protein mass spectrometry to assess the cellular response profile to drug perturbations in ovarian cancer cells for the rational desi...
ORGANISM(S): Homo sapiens (Human) 
2025-07-19 | PXD066316 | Pride
Hgsoc Ovarian cancer Cell culture Drug pertubation 
UnknownMetal complexes in cancer therapy - an update from drug design perspective.
Not available
S-EPMC5344412 | biostudies-literature
UnknownComputer-aided design of amino acid-based therapeutics: a review.
Not available
S-EPMC5958949 | biostudies-literature
UnknownComputer-Aided Drug Design: An Update.
Not available
S-EPMC9838881 | biostudies-literature
GenomicsDesign, Development, and Evaluation of Gene Therapeutics Specific to KSHV-Associated Diseases
Design, Development, and Evaluation of Gene Therapeutics Specific to KSHV-Associated Diseases
PRJNA1225617 | ENA
UnknownRational Design of Chemically Controlled Antibodies and Protein Therapeutics.
Not available
S-EPMC10278067 | biostudies-literature
UnknownThe Risks of miRNA Therapeutics: In a Drug Target Perspective.
Not available
S-EPMC7910153 | biostudies-literature
GenomicsIntegrated transcriptomic and in silico drug screening identifies potential stroma-targeting therapeutics in pancreatic cancer
Integrated transcriptomic and in silico drug screening identifies potential stroma-targeting therapeutics in pancreatic cancer
PRJNA805246 | ENA
Sort   by:  
 Page size